Home › Postural Orthostatic Tachycardia Syndrome › NCT00409435
A Study of Pyridostigmine in Postural Tachycardia Syndrome
RecruitingPhase 2
Double-Blind, Placebo-Controlled Study of Pyridostigmine in Postural Tachycardia Syndrome
Who can join
Ages 15 to 55 · All sexes
Full eligibility criteria
Inclusion Criteria: Diagnosis of postural tachycardia syndrome using the following criteria: * Orthostatic heart rate increment greater than or equal to 30 beats per minute (bpm) within 5 minutes of head-up tilt. * Symptoms of orthostatic intolerance. These include weakness, lightheadedness, blurred vision, nausea, palpitations, and difficulty with concentration and thinking. Both criteria must be fulfilled. Exclusion Criteria: * Pregnant or lactating women * Presence of failure of other organ systems or systemic illness that could affect autonomic function or the patient's ability to cooperate with the study * Hypothyroidism or hyperthyroidism * Clinically significant coronary artery disease * Medications that could interfere with autonomic testing * Previous treatment with pyridostigmine for POTS. Patients must not have taken pyridostigmine in the past month
About the study
This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.
What is being tested
- pyridostigmine (drug)
- Placebo (drug)
Sponsor: Mayo Clinic · Participants: 50 · Started: 2006-10
Contact the study team
Official record on ClinicalTrials.gov — NCT00409435
Locations in the U.S.
| Minnesota | Mayo Clinic, Rochester |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.